Transthyretin amyloid cardiomyopathy (ATTR-CM) (Formulary)

TAFAMIDIS

Important: Therapy notes

Risk minimisation materials

  • Exclude pregnancy before treatment and ensure effective contraception during and for one month after stopping treatment.

Important: Formulation and dosage details

Formulation:

Capsules 61mg (Restricted: Specialist use only)

Dosage:

  • SMC2585: for the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
  • Patients will be initiated on treatment by cardiology.
  • Patients will be reviewed 6-monthly in the cardiology clinic throughout treatment. 
  • Decision to stop can be made in primary care, eg if the patient’s clinical condition has changed and the patient is considered to have end-stage illness or unacceptable drug intolerance. Cardiology should be informed via Clinical Dialogue.

Editorial Information

Document Id: F383